JACC:低密度脂蛋白胆固醇可预测外周动脉疾病风险

2019-09-16 MedSci MedSci原创

低密度脂蛋白胆固醇(LDL-C)与冠心病的发生风险相关,但其与外周血管疾病的相关性尚不清楚。本研究的目的旨在评估LDL-C水平是否与视网膜病变、神经病变、慢性肾脏疾病(CKD)和外周动脉疾病(PAD)相关。 研究发现,高水平的LDL-C与视网膜病变和神经病变无明显相关性,而CKD和PAD与LDL-C水平呈逐步相关性(p<<0.001)。LDL-C每升高1mmol/L,视网膜病变的

低密度脂蛋白胆固醇(LDL-C)与冠心病的发生风险相关,但其与外周血管疾病的相关性尚不清楚。本研究的目的旨在评估LDL-C水平是否与视网膜病变、神经病变、慢性肾脏疾病(CKD)和外周动脉疾病(PAD)相关。

研究发现,高水平的LDL-C与视网膜病变和神经病变无明显相关性,而CKD和PAD与LDL-C水平呈逐步相关性(p<<0.001)。LDL-C每升高1mmol/L,视网膜病变的风险比为1.06 (95% CI: 0.24-4.58),神经病变的风险比是1.05 (95% CI: 0.64-1.72),CKD的风险比是3.83 (95% CI: 2.00-7.34),PAD的风险比为2.09 (95% CI: 1.30-2.38)。

研究结果显示,高水平LDL-C不与视网膜病变和神经病变相关,但会增加慢性肾脏疾病和外周动脉疾病风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-12-18 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-22 白驹过隙

    不错不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1854516, encodeId=08d6185451674, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Dec 18 21:14:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373038, encodeId=e56e3e303800, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLns60AgRWAiaQDHFDfick3eibNbPeG5dmBeA1ZltwTWwLZ5uACJzHEWjePmNtttFh91VFv0MVIa1EoQ/132, createdBy=5c2f2462933, createdName=白驹过隙, createdTime=Sun Sep 22 03:00:32 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326341, encodeId=5b8013263411f, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424750, encodeId=257f1424e505e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473194, encodeId=b2b814e3194d9, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593326, encodeId=e571159332642, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Wed Sep 18 05:14:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372793, encodeId=e3bf3e279364, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon Sep 16 14:32:08 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 天地飞扬

    学习

    0

相关资讯

JACC:经导管二尖瓣置换术在严重二尖瓣钙化患者中的应用

在有严重二尖瓣环钙化(MAC)的情况下,二尖瓣反流(MR)的治疗具有挑战性。本研究的目的旨在评估经导管二尖瓣置换术在严重MAC患者中的疗效。本研究对9名严重MAC患者(平均年龄77±6岁,男性有5名)进行了经心尖经导管二尖瓣置换术。技术成功率为100%,无操作相关的死亡。1名患者由于假体旋转不良出现了左室流出道梗阻,并成功进行酒精室间隔消融治疗。经过平均12个月的随访,出现了1例心源性死亡和1例非

JACC:非ST段抬高心梗患者院内血运重建率与出院后死亡率的相关性研究

非ST段抬高急性冠状动脉综合征(NSTE-ACS)患者院内冠状动脉血运重建率(CRR)与出院后死亡率的关系尚不清楚。本研究的目的旨在评估NSTE-ACS患者的CRR与出院后2年死亡率(2YMR)的相关性。本研究纳入分析了EPICOR临床试验中的11931名NSTE-ACS患者,基线水平患者在临床特征、药物治疗、CRR和2YMR存在明显差异,平均CRR范围为0.0% -96.8%,从罗马尼亚的12.

盘点:JACC九月第二期研究一览

1.多支冠脉搭桥术中期死亡率较单支冠脉搭桥术更低DOI: 10.1016/j.jacc.2019.06.067http://www.onlinejacc.org/content/74/10/1275本研究的目的旨在评估和比较多支冠状动脉搭桥术(MAGs)与单支冠状动脉搭桥术(SAGs)在多分支冠脉病变患者中的中期疗效。本研究纳入分析了纽约心脏注册数据库中的63402名多分支冠脉病变患者,并比较MA

砥砺前行三十载,铸造学术“心长城”|第三十届长城心脏病学会议邀您参会!

第三十届长城心脏病学会议将于2019年10月10日-13日在北京国家会议中心隆重召开!届时,来自国内外的心血管及其相关领域顶级专家将汇聚一堂,群贤毕至,盛况空前。弹指间,长城心脏病学会议已走过三十年峥嵘岁月。三十载栉风沐雨,三十载砥砺前行,三十载春华秋实。长城会三十年不平凡而光辉的历程,见证了中国心血管事业的蓬勃发展。长城心脏病学会议三十年的发展历程是一幅波澜壮阔的奋斗画卷,是一首荡气回肠的壮丽史

JACC:右心疾病通过影响纤维化和传导系统促进房颤的形成

影响右心的疾病会促进房颤的形成,但具体机制尚不清楚。本研究的目的旨在通过肺动脉高压(PH)大鼠模型探究右室疾病是否会促进房颤的发展及其发生机制。本研究通过注射野百合碱形成PH大鼠模型,并在右室疾病形成后的21天对大鼠进行分析。野百合碱可以增高大鼠右室的压力和质量,右房也会增大。在32只PH大鼠中,有32只(100%)大鼠诱发了房颤,对照组的诱发率为6%(p < 0.001)。PH大鼠有明显的

JACC:口服氟喹诺酮药物会增加主动脉和二尖瓣反流风险

近期有研究认为氟喹诺酮类药物(FQs)与心脏不良事件的发生相关,包括主动脉夹层和动脉瘤。截止目前,FQs是否会增加主动脉或二尖瓣反流风险尚不清楚。本研究的目的旨在评估FQs是否会增加主动脉或二尖瓣反流风险。本研究纳入了美国IQVIA数据库中的12505名患者和125020名对照,与阿莫西林和阿奇霉素的使用者相比,FQs使用者发生主动脉或二尖瓣反流风险的比值比(RR)为 2.40 (95% CI: